Athira Pharma (NASDAQ:ATHA) Stock Rating Lowered by Mizuho

Athira Pharma (NASDAQ:ATHA) was downgraded by equities research analysts at Mizuho from an “outperform” rating to a “neutral” rating in a research report issued on Thursday, Marketbeat Ratings reports. They presently have a $0.50 price target on the stock, down from their prior price target of $5.00. Mizuho’s price target points to a potential upside of 16.20% from the stock’s current price.

A number of other analysts also recently commented on the company. Rodman & Renshaw downgraded Athira Pharma from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 4th. BTIG Research downgraded Athira Pharma from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 4th. Finally, JMP Securities downgraded Athira Pharma from an “outperform” rating to a “market perform” rating in a research report on Wednesday, September 4th.

Athira Pharma Stock Down 7.4 %

Shares of NASDAQ:ATHA opened at $0.43 on Thursday. The business has a 50 day moving average price of $2.55 and a 200 day moving average price of $2.53. Athira Pharma has a twelve month low of $0.43 and a twelve month high of $4.30. The company has a market cap of $16.49 million, a price-to-earnings ratio of -0.14 and a beta of 2.90.

Athira Pharma (NASDAQ:ATHA) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.05. Analysts anticipate that Athira Pharma will post -2.56 EPS for the current year.

Insider Transactions at Athira Pharma

In related news, Director Kelly A. Romano bought 27,400 shares of the company’s stock in a transaction dated Monday, June 24th. The stock was acquired at an average cost of $2.42 per share, with a total value of $66,308.00. Following the acquisition, the director now owns 80,715 shares in the company, valued at approximately $195,330.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last ninety days, insiders sold 8,829 shares of company stock valued at $5,033. Corporate insiders own 19.80% of the company’s stock.

Hedge Funds Weigh In On Athira Pharma

A number of hedge funds have recently modified their holdings of the stock. American Century Companies Inc. raised its holdings in shares of Athira Pharma by 9.4% in the 2nd quarter. American Century Companies Inc. now owns 38,940 shares of the company’s stock worth $103,000 after buying an additional 3,333 shares in the last quarter. Forefront Analytics LLC increased its holdings in Athira Pharma by 43.0% during the 4th quarter. Forefront Analytics LLC now owns 29,765 shares of the company’s stock valued at $72,000 after purchasing an additional 8,955 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Athira Pharma by 3.5% during the 2nd quarter. Renaissance Technologies LLC now owns 271,488 shares of the company’s stock valued at $719,000 after purchasing an additional 9,164 shares in the last quarter. Rothschild Investment LLC acquired a new stake in Athira Pharma during the 2nd quarter valued at $34,000. Finally, Private Advisor Group LLC acquired a new stake in Athira Pharma during the 4th quarter valued at $32,000. 57.12% of the stock is owned by institutional investors and hedge funds.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.